Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.
Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore.
Zhenkun
Z
Na
Singapore Immunology Network, 8a Biomedical Grove, Singapore 138648, Singapore.
Siok Ping
SP
Yeo
Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore.
Sakshibeedu R
SR
Bharath
European Molecular Biology Laboratory, Grenoble Outstation, 71 avenue des Martyrs, CS 90181 F-38042 Grenoble, France.|Unit of Virus Host-Cell Interactions, Univ. Grenoble Alpes-EMBL-CNRS, 71 avenue des Martyrs, CS 90181 F-38042 Grenoble, France.
Matthew W
MW
Bowler
Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore.
Esra
E
Balıkçı
Singapore Immunology Network, 8a Biomedical Grove, Singapore 138648, Singapore.
Cheng-I
CI
Wang
Institute of Molecular and Cell Biology, 61 Biopolis Drive, Singapore 138673, Singapore.|Department of Biochemistry, National University of Singapore, 14 Science Drive, Singapore 117543, Singapore.
Haiwei
H
Song
D000595:Amino Acid Sequence; D000818:Animals; D019138:Antibodies, Blocking / Q000737:chemistry* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D007109:Immunity; D008024:Ligands; D051379:Mice; D061026:Programmed Cell Death 1 Receptor / Q000737:chemistry* / Q000378:metabolism; D013329:Structure-Activity Relationship
D019138:Antibodies, Blocking; D061067:Antibodies, Monoclonal, Humanized; D008024:Ligands; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab